nach oben

Current Cardiology Reports

Erschienen in:

07.10.2023 | Peripheral Vascular Disease (S Kinlay, Section Editor)

Endovascular Interventions for Peripheral Artery Disease: A Contemporary Review

verfasst von: Nathan W. Watson, Ramya C. Mosarla, Eric A. Secemsky

Erschienen in: Current Cardiology Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Peripheral artery disease (PAD) is an increasingly prevalent but frequently underdiagnosed condition that can be associated with high rates of morbidity and mortality. While an initial noninvasive approach is the cornerstone of management, revascularization is often pursued for patients with treatment-refractory claudication or chronic limb-threatening ischemia (CLTI). In this review, we discuss the current state of endovascular interventions for PAD and explore the many new emerging technologies.

Recent Findings

The last decade has resulted in numerous advances in PAD interventions including the ongoing evolution of drug-coated devices, novel approaches to complex lesions, and contemporary evidence from large clinical trials for CLTI.

Summary

Advances in endovascular management have allowed for increasingly complex lesions to be tackled percutaneously. Future directions for the field include the continued evolution in device technology, continued development of state-of-the-art techniques to revascularization of complex lesions, and increased collaboration between a largely multidisciplinary field.

Lin J, Chen Y, Jiang N, Li Z, Xu S. Burden of peripheral artery disease and its attributable risk factors in 204 countries and territories from 1990 to 2019. Front Cardiovasc Med. 2022;9:1–13.

Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Heal [Internet]. 2019;7:e1020–30. Available from: https://doi.org/10.1016/S2214-109X(19)30255-4.

Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369:448–57.CrossRefPubMed

Mensah GA, Moran AE, Roth GA, Narula J. The global burden of cardiovascular diseases, 1990–2010. Glob Heart [Internet]. 2014;9:183–4. Available from: https://doi.org/10.1016/j.gheart.2014.01.008.

• Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation. 2021;144:E171–91. Scientific statement is published by the American Heart Association for lower extremity peripheral artery disease.PubMedCentralCrossRefPubMed

Kullo I, Rooke T. Peripheral artery disease. N Engl J Med. 2016;374:861–71.CrossRefPubMed

Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017.

Bonaca MP, Creager MA. Pharmacological Treatment and current management of peripheral artery disease. Circ Res. 2015;116:1579–98.CrossRefPubMed

Hageman D, de Wit MWAJM, van den Houten MML, Gommans LNM, Scheltinga MRM, Teijink JAW. Vascular quality of life questionnaire-6 before and after supervised exercise therapy in patients with intermittent claudication. Eur J Vasc Endovasc Surg [Internet]. 2022;63:457–63. Available from: https://doi.org/10.1016/j.ejvs.2021.10.031.

10.

Fokkenrood HJP, Bendermacher BLW, Lauret GJ, Willigendael EM, Prins MH, Teijink JAW. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2013.

11.

Saxon JT, Safley DM, Mena-Hurtado C, Heyligers J, Fitridge R, Shishehbor M, et al. Adherence to guideline-recommended therapy—including supervised exercise therapy referral—across peripheral artery disease specialty clinics: insights from the International PORTRAIT Registry. J Am Heart Assoc. 2020;9:1–9.CrossRef

12.

Klein AJ, Jaff MR, Gray BH, Aronow HD, Bersin RM, Diaz-Sandoval LJ, et al. SCAI appropriate use criteria for peripheral arterial interventions: an update. Catheter Cardiovasc Interv. 2017;90:E90-110.CrossRefPubMed

13.

Farber A. Chronic limb-threatening ischemia. N Engl J Med. 2018;379:171–80.

14.

Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. Circ Res. 2015;116:1599–613.PubMedCentralCrossRefPubMed

15.

Raja A, Secemsky EA. Late mortality and paclitaxel-coated devices: has the controversy finally come to an end? J Soc Cardiovasc Angiogr Interv [Internet]. 2023;2:100981. Available from: https://doi.org/10.1016/j.jscai.2023.100981.

16.

Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7.

17.

Secemsky EA, Shen C, Schermerhorn M, Yeh RW. Longitudinal assessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries the SAFE-PAD study. JAMA Intern Med. 2021;181:1071–80.CrossRefPubMed

18.

Nordanstig J, James S, Andersson M, Andersson M, Danielsson P, Gillgren P, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med. 2020;383:2538–46.CrossRefPubMed

19.

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:5–67.CrossRef

20.

Silva JC. BEST-CLI versus BASIL-2 Trial: conflicting results? Port J Card Thorac Vasc Surg Editor. 2023;11–2.

21.

Bradbury AW, Adam DJ, Beard JD, Cleveland T, Forbes JF, Fowkes FGR, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–34.CrossRefPubMed

22.

Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FGR, Gillespie I, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg [Internet]. 2010;51:5S-17S. Available from: https://doi.org/10.1016/j.jvs.2010.01.073.

23.

Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FGR, Gillespie I, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg [Internet]. 2010;51:18S-31S. Available from: https://doi.org/10.1016/j.jvs.2010.01.074.

24.

•• Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med. 2022;387:2305–16. BEST-CLI is a recently published RCT which compared surgery to endovascular therapy for CLTI. This contemporary trial assists in defining the role of each intervention for patients with and without a viable saphenous vein conduit.CrossRefPubMed

25.

•• Bradbury AW, Moakes CA, Popplewell M, Meecham L, Bate GR, Kelly L, et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation pr. Lancet [Internet]. 2023;401:1798–809. Available from: https://doi.org/10.1016/S0140-6736(23)00462-2. BASIL-2 is a recently published RCT which compared bypass surgery and endovascular therapy for patients with CLTI due to an infra-popliteal PAD. This study found improved amputation-free survival with endovascular therapy.

26.

Paisley MJ, Adkar S, Sheehan BM, Stern JR. Aortoiliac occlusive disease. Semin Vasc Surg [Internet]. 2022;35:162–71. Available from: https://doi.org/10.1053/j.semvascsurg.2022.04.005.

27.

Salem M, Hosny MS, Francia F, Sallam M, Saratzis A, Saha P, et al. Management of extensive aorto-iliac disease: a systematic review and meta-analysis of 9319 patients. Cardiovasc Intervent Radiol [Internet]. 2021;44:1518–35. Available from: https://doi.org/10.1007/s00270-021-02785-6.

28.

Tetteroo E, Van Der Graaf Y, Bosch JL, Van Engelen AD, Hunink MGM, Eikelboom BC, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Lancet. 1998;351:1153–9.CrossRefPubMed

29.

Willemjin Klein;, Graaf; Y can der, Seegers; J. Dutch Iliac Stent Trial: Long-term results in patients randomized for primary or selective stent placement. Radiology. 2006;238:734–44.

30.

Goode SD, Cleveland TJ, Gaines PA. Randomized clinical trial of stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial). Br J Surg. 2013;100:1148–53.CrossRefPubMed

31.

Ye W, Liu CW, Ricco JB, Mani K, Zeng R, Jiang J. Early and late outcomes of percutaneous treatment of TransAtlantic Inter-Society Consensus class C and D aorto-iliac lesions. J Vasc Surg. 2011;53:1728–37.CrossRefPubMed

32.

Kereiakes DJ, Virmani R, Hokama JY, Illindala U, Mena-Hurtado C, Holden A, et al. Principles of intravascular lithotripsy for calcific plaque modification. JACC Cardiovasc Interv. 2021;14:1275–92.CrossRefPubMed

33.

Dini CS, Tomberli B, Mattesini A, Ristalli F, Valente S, Stolcova M, et al. Intravascular lithotripsy for calcific coronary and peripheral artery stenoses. EuroIntervention. 2019;15:714–21.CrossRefPubMed

34.

• Mosarla RC, Armstrong E, Bitton-Faiwiszewski Y, Schneider PA, Secemsky EA. State-of-the-art endovascular therapies for the femoropopliteal segment: are we there yet? J Soc Cardiovasc Angiogr Interv [Internet]. 2022;1:100439. Available from: https://doi.org/10.1016/j.jscai.2022.100439. State-of-the-art review of modern endovascular therapies for peripheral artery disease within the femoropopliteal segment.

35.

Caradu C, Lakhlifi E, Colacchio EC, Midy D, Bérard X, Poirier M, et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg. 2019;70:981-995.e10.CrossRefPubMed

36.

Schillinger M, Sabeti S, Loewe C, Dick P, Amigh J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–88.CrossRefPubMed

37.

Müller-Hülsbeck S, Benko A, Soga Y, Fujihara M, Iida O, Babaev A, et al. Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–75.CrossRefPubMed

38.

Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392:1541–51.CrossRefPubMed

39.

Farhan S, Enzmann FK, Bjorkman P, Kamran H, Zhang Z, Sartori S, et al. Revascularization strategies for patients with femoropopliteal peripheral artery disease. J Am Coll Cardiol. 2023;81:358–70.CrossRefPubMed

40.

Butala NM, Chandra V, Beckman JA, Parikh SA, Lookstein R, Misra S, et al. Contextualizing the BEST-CLI trial results in clinical practice. J Soc Cardiovasc Angiogr Interv [Internet]. 2023;2:101036. Available from: https://doi.org/10.1016/j.jscai.2023.101036.

41.

Abu Dabrh AM, Steffen MW, Asi N, Undavalli C, Wang Z, Elamin MB, et al. Bypass surgery versus endovascular interventions in severe or critical limb ischemia. J Vasc Surg [Internet]. 2016;63:244–253.e11. Available from: https://doi.org/10.1016/j.jvs.2015.07.068.

42.

Armstrong EJ, Bishu K, Waldo SW. Endovascular treatment of infrapopliteal peripheral artery disease. Curr Cardiol Rep. 2016;18:1–7.CrossRef

43.

Fernandez N, McEnaney R, Marone LK, Rhee RY, Leers S, Makaroun M, et al. Multilevel versus isolated endovascular tibial interventions for critical limb ischemia. J Vasc Surg [Internet]. 2011;54:722–9. Available from: https://doi.org/10.1016/j.jvs.2011.03.232.

44.

Söderström MI, Arvela EM, Korhonen M, Halmesmäki KH, Albäck AN, Biancari F, et al. Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: a propensity score analysis. Ann Surg. 2010;252:765–72.CrossRefPubMed

45.

Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the Achilles trial. J Am Coll Cardiol. 2012;60:2290–5.CrossRefPubMed

46.

Spreen MI, Martens JM, Hansen BE, Knippenberg B, Verhey E, Van Dijk LC, et al. Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia (PADI) trial. Circ Cardiovasc Interv. 2016;9:1–10.CrossRef

47.

Fusaro M, Cassese S, Ndrepepa G, Tepe G, King L, Ott I, et al. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. JACC Cardiovasc Interv [Internet]. 2013;6:1284–93. Available from: https://doi.org/10.1016/j.jcin.2013.08.007.

48.

Liistro F, Angioli P, Ventoruzzo G, Ducci K, Reccia MR, Ricci L, et al. Randomized controlled trial of Acotec drug-eluting balloon versus plain balloon for below-the-knee angioplasty. JACC Cardiovasc Interv [Internet]. 2020;13:2277–86. Available from: https://doi.org/10.1016/j.jcin.2020.06.045.

49.

Liistro F, Porto I, Angioli P, Grotti S, Ricci L, Ducci K, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–21.CrossRefPubMed

50.

Ipema J, Huizing E, Schreve MA, de Vries JPPM, Ünlü Ç. Editor’s Choice – Drug coated balloon angioplasty vs. standard percutaneous transluminal angioplasty in below the knee peripheral arterial disease: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2020;59:265–75.

51.

Kum S, Tan YK, Schreve MA, Ferraresi R, Varcoe RL, Schmidt A, et al. Midterm outcomes from a pilot study of percutaneous deep vein arterialization for the treatment of no-option critical limb ischemia. J Endovasc Ther. 2017;24:619–26.CrossRefPubMed

52.

Schmidt A, Schreve MA, Huizing E, Del Giudice C, Branzan D, Ünlü Ç, et al. Midterm outcomes of percutaneous deep venous arterialization with a dedicated system for patients with no-option chronic limb-threatening ischemia: the ALPS multicenter study. J Endovasc Ther [Internet]. 2020;27:658–65. Available from: https://doi.org/10.1177/1526602820922179.

53.

• Clair DG, Mustapha JA, Shishehbor MH, Schneider PA, Henao S, Bernardo NN, et al. PROMISE I: early feasibility study of the LimFlow System for percutaneous deep vein arterialization in no-option chronic limb-threatening ischemia: 12-month results. J Vasc Surg [Internet]. 2021;74:1626–35. Available from: https://doi.org/10.1016/j.jvs.2021.04.057. PROMISE I demonstrated early safety and efficacy of the LimFlow pDVA percutaneous deep vein arterialization platform in patients with no option CLTI.

54.

Shishehbor MH, Powell RJ, Montero-Baker MF, Dua A, Martínez-Trabal JL, Bunte MC, et al. Transcatheter arterialization of deep veins in chronic limb-threatening ischemia. N Engl J Med. 2023;388:1171–80.CrossRefPubMed

55.

• Krievins DK, Halena G, Scheinert D, Savlovskis J, Szopiński P, Krämer A, et al. One-year results from the DETOUR I trial of the PQ Bypass DETOUR System for percutaneous femoropopliteal bypass. J Vasc Surg. 2020;72:1648-1658.e2. The DETOUR I trial found that the PQ Bypass DETOUR percutaneous femoropopliteal bypass platform was safe and efficacious for patients with long segment femoropopliteal disease at one year of follow-up.CrossRefPubMed

56.

Vanderland M, Ooi YS, Gray WA. Device profile of the Tack Endovascular System® for the treatment of peripheral arterial disease: overview of safety and efficacy. Expert Rev Med Devices [Internet]. 2021;18:717–26. Available from: https://doi.org/10.1080/17434440.2021.1947243.

57.

Kobayashi N, Hirano K, Yamawaki M, Araki M, Sakai T, Sakamoto Y, et al. Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease. J Vasc Surg [Internet]. 2018;67:1151–8. Available from: https://doi.org/10.1016/j.jvs.2017.08.092.

58.

Gasper WJ, Runge SJ, Owens CD. Management of infrapopliteal peripheral arterial occlusive disease. Curr Treat Options Cardiovasc Med. 2012;14:136–48.CrossRefPubMed

59.

Horie K, Tanaka A, Taguri M, Kato S, Inoue N. Impact of prolonged inflation times during plain balloon angioplasty on angiographic dissection in femoropopliteal lesions. J Endovasc Ther. 2018;25:683–91.CrossRefPubMed

60.

Siah MC, Babb J, Schneider PA. How i do it: optimizing angioplasty utilizing the tack endovascular system in the management of CLTI. J Vasc Surg Cases, Innov Tech [Internet]. 2023;101206. Available from: https://doi.org/10.1016/j.jvscit.2023.101206.

61.

Brodmann M, Wissgott C, Brechtel K, Nikol S, Zeller T, Lichtenberg M, et al. Optimized drug-coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: TOBA III 12-month results. J Vasc Surg [Internet]. 2020;72:1636–1647.e1. Available from: https://doi.org/10.1016/j.jvs.2020.01.078.

62.

Gray WA, Cardenas JA, Brodmann M, Werner M, Bernardo NI, George JC, et al. Treating post-angioplasty dissection in the femoropopliteal arteries using the tack endovascular system: 12-month results from the TOBA II Study. JACC Cardiovasc Interv [Internet]. 2019;12:2375–84. Available from: https://doi.org/10.1016/j.jcin.2019.08.005.

63.

Geraghty PJ, Adams G, Schmidt A, Cardenas J, Lichtenberg M, Wissgott C, et al. Six-month pivotal results of tack optimized balloon angioplasty using the Tack Endovascular System in below-the-knee arteries. J Vasc Surg [Internet]. 2021;73:918–929.e5. Available from: https://doi.org/10.1016/j.jvs.2020.08.135.

64.

Darmoch F, Alraies MC, Al-Khadra Y, Pacha HM, Pinto DS, Osborn EA. Intravascular ultrasound imaging–guided versus coronary angiography–guided percutaneous coronary intervention: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9.

65.

Fazel R, Yeh RW, Cohen D, Rao SV, Song Y, Secemsky EA. Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA. Eur Heart J. 2023;00:1–11.

66.

Divakaran S, Parikh SA, Hawkins BM, Chen S, Song Y, Banerjee S, et al. Temporal trends, practice variation, and associated outcomes with IVUS Use during peripheral arterial intervention. JACC Cardiovasc Interv. 2022;15:2080–90.PubMedCentralCrossRefPubMed

67.

Nicolas W. Shammas ; James T. Torey; W. John Shammas; Susan Jones-Miller; Gail A. Shammas. Intravascular ultrasound assessment and correlation with angiographic findings demonstrating femoropopliteal arterial dissections post atherectomy: results from the iDissection Study. J Invasive Cardiol. 2018;30:240–4.

68.

Allan RB, Puckridge PJ, Spark JI, Delaney CL. The Impact of intravascular ultrasound on femoropopliteal artery endovascular interventions: a randomized controlled trial. JACC Cardiovasc Interv. 2022;15:536–46.CrossRefPubMed

69.

• Secemsky EA, Mosarla RC, Rosenfield K, Kohi M, Lichtenberg M, Meissner M, et al. Appropriate use of intravascular ultrasound during arterial and venous lower extremity interventions. JACC Cardiovasc Interv. 2022;15:1558–68. The first published consensus opinion for intravascular ultrasound for venous and arterial peripheral interventions.CrossRefPubMed

70.

Armstrong EJ, Soukas PA, Shammas N, Chamberlain J, Pop A, Adams G, et al. Intravascular lithotripsy for treatment of calcified, stenotic iliac arteries: a cohort analysis from the Disrupt PAD III Study. Cardiovasc Revascularization Med [Internet]. 2020;21:1262–8. Available from: https://doi.org/10.1016/j.carrev.2020.02.026.

71.

Beckman JA, Schneider PA, Conte MS. Advances in revascularization for peripheral artery disease: revascularization in PAD. Circ Res. 2021;128:1885–912.CrossRefPubMed

72.

Kawaguchi R, Tsurugaya H, Hoshizaki H, Toyama T, Oshima S, Taniguchi K. Impact of lesion calcification on clinical and angiographic outcome after sirolimus-eluting stent implantation in real-world patients. Cardiovasc Revascularization Med. 2008;9:2–8.CrossRef

73.

Babaev AA, Zavlunova S, Attubato MJ, Martinsen BJ, Mintz GS, Maehara A. Orbital atherectomy plaque modification assessment of the femoropopliteal artery via intravascular ultrasound (TRUTH Study). Vasc Endovascular Surg. 2015;49:188–94.PubMedCentralCrossRefPubMed

74.

Brodmann M, Werner M, Holden A, Tepe G, Scheinert D, Schwindt A, et al. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019;93:335–42.CrossRefPubMed

75.

• Tepe G, Brodmann M, Werner M, Bachinsky W, Holden A, Zeller T, et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the randomized Disrupt PAD III Trial. JACC Cardiovasc Interv. 2021;14:1352–61. The Disrupt PAD III trial compared IVL to PTA prior to management with a DCB or stenting for calcified femoropopliteal lesions and found IVL to be an effective strategy.CrossRefPubMed

76.

Tepe G, Brodmann M, Bachinsky W, Holden A, Zeller T, Mangalmurti S, et al. Intravascular lithotripsy for peripheral artery calcification: mid-term outcomes from the randomized Disrupt PAD III Trial. J Soc Cardiovasc Angiogr Interv [Internet]. 2022;1:100341. Available from: https://doi.org/10.1016/j.jscai.2022.100341.

77.

Kassimis G, Spiliopoulos S, Katsanos K, Tsetis D, Krokidis ME. Bioresorbable scaffolds in peripheral arterial disease. Expert Rev Cardiovasc Ther. 2014;12:443–50.CrossRefPubMed

78.

van Haelst STW, Peeters Weem SMO, Moll FL, de Borst GJ. Current status and future perspectives of bioresorbable stents in peripheral arterial disease. J Vasc Surg [Internet]. 2016;64:1151–1159.e1. Available from: https://doi.org/10.1016/j.jvs.2016.05.044.

79.

Lammer J, Bosiers M, Deloose K, Schmidt A, Zeller T, Wolf F, et al. Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): 2-year clinical and imaging results. JACC Cardiovasc Interv [Internet]. 2016;9:1178–87. Available from: https://doi.org/10.1016/j.jcin.2016.02.051.

80.

Varcoe RL, Parikh SA, DeRubertis BG, Jones-McMeans JM, Teraphongphom NT, Wang J, et al. Evaluation of an infrapopliteal drug-eluting resorbable scaffold: design methodology for the LIFE-BTK randomized controlled trial. J Soc Cardiovasc Angiogr Interv [Internet]. 2023;2:100964. Available from: https://doi.org/10.1016/j.jscai.2023.100964.

81.

Feiring AJ, Krahn M, Nelson L, Wesolowski A, Eastwood D, Szabo A. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents. The PaRADISE (PReventing Amputations using Drug eluting StEnts) Trial. J Am Coll Cardiol. 2010;55:1580–9.

82.

Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg [Internet]. 2012;55:390–8. Available from: https://doi.org/10.1016/j.jvs.2011.07.099.

83.

Rastan A, Brechtel K, Krankenberg H, Zahorsky R, Tepe G, Noory E, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol [Internet]. 2012;60:587–91. Available from: https://doi.org/10.1016/j.jacc.2012.04.035.

84.

Patel A, Irani FG, Pua U, Tay KH, Chong TT, Leong S, et al. Randomized controlled trial comparing drug-coated balloon angioplasty versus conventional balloon angioplasty for treating below-the-knee arteries in critical limb ischemia: the SINGA-PACLI trial. Radiology. 2021;300:715–24.CrossRefPubMed

85.

Zeller T, Beschorner U, Pilger E, Bosiers M, Deloose K, Peeters P, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-First in Man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subject. JACC Cardiovasc Interv. 2015;8:1614–22.

86.

Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT deep randomized trial. J Am Coll Cardiol. 2014;64:1568–76.

87.

Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048–56.CrossRefPubMed

Titel: Endovascular Interventions for Peripheral Artery Disease: A Contemporary Review
verfasst von: Nathan W. Watson
Ramya C. Mosarla
Eric A. Secemsky
Publikationsdatum: 07.10.2023
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 11/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01973-9

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Endovascular Interventions for Peripheral Artery Disease: A Contemporary Review

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

TAVR in TAVR: Where Are We in 2023 for Management of Failed TAVR Valves?

Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan

Preventing Heart Failure Readmission in Patients with Low Socioeconomic Position

Advances in Screening for Radiation-Associated Cardiotoxicity in Cancer Patients

Contraception and Cardiovascular Effects: What Should the Cardiologist Know?

Contrast Echocardiography for Assessing Myocardial Perfusion

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie